Literature DB >> 15208644

Interferon type I gene expression in chronic hepatitis C.

Sabine Mihm1, Michael Frese, Volker Meier, Perdita Wietzke-Braun, Jens-Gerd Scharf, Ralf Bartenschlager, Giuliano Ramadori.   

Abstract

Hepatitis C virus (HCV) frequently causes chronic liver disease. The cause of viral persistence might be an inappropriate type I interferon (IFN) induction. To analyze the host's IFN response in chronic hepatitis C, we measured the transcription level of type I IFN genes as well as type I IFN-regulated genes in liver tissue and corresponding blood samples from patients with chronic hepatitis C, nonviral liver diseases, and a suspected but later excluded liver disease. Competitive and real-time RT-PCR assays were used to quantify the messenger RNA (mRNA) levels of all known IFN-alpha, IFN-beta, and IFN-lambda genes and those of some IFN-regulated genes. We failed to detect any hepatic type I IFN mRNA induction, although liver tissue of chronic hepatitis C patients contained high numbers of some type I IFN-inducible effector mRNA molecules. Analysis of peripheral blood samples, however, showed a clear type I IFN induction. Parallel experiments employing HCV replicon cell lines revealed that replication of HCV RNA is not sufficient to induce any type I IFN nor to induce directly type I IFN-regulated genes such as MxA. In conclusion, our data provide evidence for the absence of an induction of type I IFN genes by HCV in the human liver and argue for a further development of type I IFN-based therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15208644     DOI: 10.1038/labinvest.3700135

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  36 in total

Review 1.  Interferon-lambda in the immune response to hepatitis B virus and hepatitis C virus.

Authors:  Nicole E Pagliaccetti; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2010-08       Impact factor: 2.607

2.  Expression of type III interferon (IFN) in the vaginal mucosa is mediated primarily by dendritic cells and displays stronger dependence on NF-kappaB than type I IFNs.

Authors:  Marie B Iversen; Nina Ank; Jesper Melchjorsen; Søren R Paludan
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

Review 3.  IFN-λs.

Authors:  Sergei V Kotenko
Journal:  Curr Opin Immunol       Date:  2011-08-15       Impact factor: 7.486

Review 4.  Dendritic cells in hepatitis C virus infection: key players in the IFNL3-genotype response.

Authors:  Kate S O'Connor; Jacob George; David Booth; Golo Ahlenstiel
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

5.  The induction of type I interferon production in hepatitis C-infected patients.

Authors:  Lawrence M Pfeffer; Margaret A Madey; Caroline A Riely; Jaquelyn F Fleckenstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

6.  Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus.

Authors:  Julia Diegelmann; Florian Beigel; Kathrin Zitzmann; Artur Kaul; Burkhard Göke; Christoph J Auernhammer; Ralf Bartenschlager; Helmut M Diepolder; Stephan Brand
Journal:  PLoS One       Date:  2010-12-08       Impact factor: 3.240

Review 7.  Innate immune evasion by hepatitis C virus and West Nile virus.

Authors:  Brian C Keller; Cynthia L Johnson; Andrea Kaup Erickson; Michael Gale
Journal:  Cytokine Growth Factor Rev       Date:  2007-08-16       Impact factor: 7.638

8.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

Review 9.  IL28B polymorphisms as a pretreatment predictor of response to HCV treatment.

Authors:  Christoph T Berger; Arthur Y Kim
Journal:  Infect Dis Clin North Am       Date:  2012-12       Impact factor: 5.982

10.  Functional impact of endotoxin receptor CD14 polymorphisms on transcriptional activity.

Authors:  Jasmin Mertens; Rusudan Bregadze; Ashham Mansur; Eva Askar; Heike Bickeböller; Giuliano Ramadori; Sabine Mihm
Journal:  J Mol Med (Berl)       Date:  2009-05-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.